Shares of Alembic Pharmaceuticals Ltd were trading in the red and 1% lower on 29 October despite the company announcing securing final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Ticagrelor tablets 60mg.

The pills are intended to reduce the risk of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI, according to the company, adding that they are superior to clopidogrel for at least the first 12 months after ACS.

The authorised ANDA is therapeutically equivalent to the reference-listed medication Brilinta Tablets, 60 mg from AstraZeneca Pharmaceuticals LP.

The tablets, according to Alembic Pharma, also reduce the risk of stent thrombosis in patients who have been stented for ACS treatment, to reduce the risk of a first MI or stroke in patients with coronary artery disease who are at high risk for such events, and to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attacks.

According to IQVIA, the tablet market is expected to be worth $236 million in the 12 months ending June 2025.

Alembic Pharma stated that it had already gained final approval for the 90mg tablets.

The company has received a total of 227 ANDA approvals from the US FDA. There are 206 final approvals and 21 tentative clearances.

At 3:30 pm, the shares of Alembic Pharma closed 0.62% higher at Rs 900 on NSE.

Tired of missing hot stocks? Unicorn Signals provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!